Theoretical evaluation of antiemetic effects of 5-HT3 receptor antagonists for prevention of vomiting induced by cisplatin
5-HT3 receptor antagonists are widely used as antiemetic agents in clinical setting, of which palonosetron, with a long elimination half life (t 1/2), has recently become available. It is important to evaluate the concentration of serotonin when investigating the antiemetic effects of 5-HT3 receptor antagonists, as those effects are not based solely on the t 1/2 value. We theoretically evaluated the antiemetic effects of three 5-HT3 receptor antagonists (granisetron, azasetron, palonosetron) on cisplatin-induced nausea and vomiting by estimating the time course of the 5-HT3 receptor occupancy of serotonin. We estimated the 5-HT3 receptor occupancy of serotonin in the small intestine, based on the time course of plasma concentration of each 5-HT3 receptor antagonist and the time course of concentration of serotonin near the 5-HT3 receptor in the small intestine after administration of cisplatin. The antiemetic effect of each 5-HT3 receptor antagonist was evaluated based on the normal level of 5-HT3 receptor occupancy of serotonin. Our results suggest that an adequate antiemetic effect will be provided when a dose of 75 mg/m2 of cisplatin is given to patients along with any single administration of granisetron, azasetron, or palonosetron at a usual dose. On the other hand, the 5-HT3 receptor occupancy of serotonin was found to be significantly lower than normal for several days after administration of palonosetron, as compared to granisetron and azasetron, indicating that constipation may be induced. Our results show that granisetron, azasetron, and palonosetron each have an adequate antiemetic effect after administration of 75 mg/m2 of cisplatin.
Keywords5-HT3 receptor antagonist Antiemetic effect Constipation Cisplatin 5-HT3 receptor occupancy of serotonin
Conflict of interest
The authors declare no conflict of interest.
- Igarashi S, Tanaka K, Yamamura H, Sawai K, Isobe M, Masui H, Kataoka H, Ishikawa M, Oka T (1992) Phase I study of Y-25130, a new 5-HT3 receptor antagonist––single intravenous administration. Clin Rep 26(6):2535–2547Google Scholar
- Kumakura H, Koyanagi J, Nishioka Y, Sato M, Nakajima T, Nakahira K, Tateno M (1990) Phase I study of granisetron (second report)––pharmacokinetics of granisetron following single and repeat intravenous drip infusion in Japanese healthy volunteers. Rinsho Iyaku 6(Suppl. 5):25–34Google Scholar
- Yamada Y, Sugiura M, Higo K, Ozeki T, Takayanagi R, Okuyama K, Yamamoto K, Satoh H, Sawada Y, Iga T (2004) Receptor occupancy theory-based analysis of antiemetic effects and standard doses of 5-HT3 receptor antagonists in cancer patients. Cancer Chemother Pharmacol 54(2):185–190. doi: 10.1007/s00280-004-0798-x CrossRefPubMedGoogle Scholar
- Yamada Y, Fujita M, Okuyama K, Takayanagi R, Ozeki T, Yokoyama H, Iga T (2007) Analysis of antiemetic effect of various dosage regimens of azasetron hydrochloride based on 5-HT3 receptor occupancy of serotonin. Yakugaku Zasshi 127(2):353–357 (pii:JST.JSTAGE/yakushi/127.353)CrossRefPubMedGoogle Scholar